{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:48:34Z","timestamp":1782377314421,"version":"3.54.5"},"reference-count":47,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nanjing Science and Technology Plan Project","award":["202304009"],"award-info":[{"award-number":["202304009"]}]},{"name":"Natural Science Foundation of the Jiangsu Higher Education Institutions of China","award":["24KJA350004"],"award-info":[{"award-number":["24KJA350004"]}]},{"name":"Natural Science Foundation of the Jiangsu Higher Education Institutions of China","award":["23KJB360016"],"award-info":[{"award-number":["23KJB360016"]}]},{"name":"Taizhou Natural Science Foundation","award":["TZ202511"],"award-info":[{"award-number":["TZ202511"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Treatment of inflammatory bowel disease (IBD) remains a major medical challenge due to the lack of safe and effective therapeutic agents. JAK1 has been validated as a key therapeutic target that modulates the pathological progression of IBD. In this study, using tofacitinib as the lead compound, we adopted a scaffold growth strategy to design and synthesize a series of pyrrolo [2,3-b] pyridine derivatives as novel JAK1 inhibitors for the treatment of IBD. Among them, compound 15 exerted potent inhibitory activity against JAK1 with an IC50 value of 0.48 nM. Western blot results showed that compound 15 significantly inhibited LPS-induced STAT1\/3 phosphorylation in RAW264.7 cells. In addition, 15 exhibited satisfactory metabolic stability and oral bioavailability. In the DSS-induced colitis model, 15 remarkably ameliorated inflammatory symptoms, promoted epithelial repair, and inhibited the production of pro-inflammatory cytokines such as TNF-\u03b1 and IL-6. Therefore, compound 15 is regarded as a promising candidate for the treatment of IBD.<\/jats:p>","DOI":"10.3390\/molecules31132236","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:14:12Z","timestamp":1782375252000},"page":"2236","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of Pyrrolo [2,3-b] Pyridine Derivatives as Novel JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"31","author":[{"given":"Shuai","family":"Wen","sequence":"first","affiliation":[{"name":"College of Pharmacy, Taizhou University, Taizhou 225300, China"},{"name":"Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Xiao","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Min","family":"Du","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ji","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Taizhou University, Taizhou 225300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Kai","family":"Sha","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Taizhou University, Taizhou 225300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Xin-Wang","family":"Lin","sequence":"additional","affiliation":[{"name":"Nanjing Linkinovo Biological Technology Research Institute, Nanjing 211100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Mou","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Taizhou University, Taizhou 225300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[{"name":"Nanjing Linkinovo Biological Technology Research Institute, Nanjing 211100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1671-1582","authenticated-orcid":false,"given":"Zheng-Yu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"111805","DOI":"10.1016\/j.ejmech.2019.111805","article-title":"Discovery of small-molecule candidates against inflammatory bowel disease","volume":"185","author":"Bai","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK\u2013STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: Cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"117384","DOI":"10.1016\/j.ejmech.2025.117384","article-title":"Discovery of \u03b2-amino acid substituted naphthalene sulfonamide derivatives as potent Kelch-like ECH-associated protein 1\u2212nuclear factor erythroid 2-related factor 2 (Keap1\u2212Nrf2) protein\u2212protein interaction inhibitors for ulcerative colitis management","volume":"288","author":"Zhao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11949","DOI":"10.1021\/acs.jmedchem.2c00390","article-title":"Discovery of Novel Imidazo [4,5-c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"118374","DOI":"10.1016\/j.ejmech.2025.118374","article-title":"Development of potent JAK1\/2 PROTAC degraders for the treatment of inflammatory bowel diseases","volume":"302","author":"Li","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.pharep.2014.04.005","article-title":"Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases","volume":"66","author":"Sobczak","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","article-title":"IBD immunopathogenesis: A comprehensive review of inflammatory molecules","volume":"16","author":"Park","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/acs.jmedchem.0c01468","article-title":"Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1021\/acs.jmedchem.1c01137","article-title":"Identification of a Novel 2,8-Diazaspiro [4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2\/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2478\/pjvs-2013-0025","article-title":"Cytokines in canine inflammatory bowel disease","volume":"16","author":"Rychlik","year":"2013","journal-title":"Pol. J. Vet. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.mpg.0000226374.18494.14","article-title":"The Role of Pro-Inflammatory Cytokines in Inflammatory Bowel Disease Growth Retardation","volume":"43","author":"Wong","year":"2006","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/rheumatology\/keab024","article-title":"JAK1: Number one in the family; number one in inflammation?","volume":"60","author":"Spinelli","year":"2021","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izy364","article-title":"A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function","volume":"25","author":"Duarte","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.jmedchem.9b01439","article-title":"Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease","volume":"63","author":"Leonard","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pharmthera.2018.07.003","article-title":"Targeting JAK-STAT signal transduction in IBD","volume":"192","author":"Soendergaard","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mou, Y., Wen, S., Wang, Y., Zhao, Y., Li, Y.-P., Sha, H.-K., Gui, L.-J., Jiang, Z.-Y., and Xu, X.-M. (2025). Discovery of Novel Tofacitinib\u2013ADTOH Molecular Hybridization Derivatives for the Treatment of Ulcerative Colitis. Antioxidants, 14.","DOI":"10.3390\/antiox14030325"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Xu, L., Xu, F., Yao, Q., and Wong, V.K.W. (2025). Ruxolitinib alleviates DSS-induced acute ulcerative colitis by inhibiting STAT1 phosphorylation and reducing MDSC infiltration. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1572534"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1021\/acs.jmedchem.5c03563","article-title":"Identification of 2,4-Diaminopyrimidine Derivatives as Novel Gut-Restricted Selective JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease","volume":"69","author":"Yue","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"STATs: Transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/emboj\/21.7.1754","article-title":"Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-alpha","volume":"21","author":"McBride","year":"2002","journal-title":"EMBO J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: First Approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases","volume":"191","author":"Galien","year":"2013","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo [2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/1744666X.2018.1532291","article-title":"Tofacitinib for the treatment of ulcerative colitis","volume":"14","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/13543784.2016.1189900","article-title":"Tofacitinib for the treatment of ulcerative colitis","volume":"25","author":"Izzo","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn\u2019s Disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1021\/acs.jmedchem.1c02166","article-title":"Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA\u2013PABA\u2013MAC and 5-ASA\u2013PABA\u2013Diamine for the Treatment of Ulcerative Colitis","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","article-title":"Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis","volume":"19","author":"Deepak","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/codi.15702","article-title":"Perioperative safety of tofacitinib in surgical ulcerative colitis patients","volume":"23","author":"Lightner","year":"2021","journal-title":"Color. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8725","DOI":"10.1021\/acs.jmedchem.3c00372","article-title":"Discovery of 1H-Imidazo [4,5-b]pyridine Derivatives as Potent and Selective BET Inhibitors for the Management of Neuropathic Pain","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"116080","DOI":"10.1016\/j.ejmech.2023.116080","article-title":"Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis","volume":"265","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11062","DOI":"10.1021\/acs.jmedchem.5c00040","article-title":"Rational Design of Novel Quinazolinone\u2013Pyrrolodihydropyrrolone Analogs as PIM\/HDAC Dual-Target Inhibitors for the Treatment of Acute Myelocytic Leukemia","volume":"68","author":"Xin","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1021\/acs.jmedchem.1c00682","article-title":"Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid Cell Leukemia 1 Inhibitors with High Affinity, Selectivity, and Oral Bioavailability","volume":"64","author":"Zhu","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e202501062","DOI":"10.1002\/cmdc.202501062","article-title":"Discovery of a Prodrug of Bardoxolone Methyl for the Treatment of Acute Lung Injury","volume":"21","author":"Wen","year":"2026","journal-title":"ChemMedChem"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhu, T., Tu, J., Sun, S., Zhao, Z., Lu, H., Wen, S., Xu, S., Ge, Y., You, Q., and Sheng, C. (Acta Pharm. Sin. B, 2026). A bioorthogonal antifungal system driven by an all-in-one tetrazine reagent for precise imaging and therapy, Acta Pharm. Sin. B, in press.","DOI":"10.1016\/j.apsb.2026.05.016"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1021\/acs.jmedchem.0c01116","article-title":"Design, Synthesis, and Structure\u2013Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein\u2013Protein Interaction Inhibitors","volume":"63","author":"Zhou","year":"2020","journal-title":"J. Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/13\/2236\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:15:07Z","timestamp":1782375307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/13\/2236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":47,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["molecules31132236"],"URL":"https:\/\/doi.org\/10.3390\/molecules31132236","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}